NT-proBNP Antibodies & Antigens: NT-proBNP as a Cardiac Biomarker in Cats and Dogs
Validation data of GeneMedi's products
- Feline NT-proBNP
Detection performance and stability evaluation of GeneMedi's anti-Feline NT-proBNP antibodies
GeneMedi's anti-Feline NT-proBNP antibody pairs offer excellent sensitivity, specificity, and stability, making them ideal for diagnostic assay development. They enable reliable detection across a broad concentration range with low EC50 and detection limits, while showing minimal cross-reactivity with canine and human NT-proBNP. Stability tests under diverse storage conditions confirm their robustness for both research and diagnostic applications.
Fig 1. Detection performance and stability evaluation of GeneMedi's anti-Feline NT-proBNP antibodies
A–B. Detection curves of feline NT-proBNP. The low EC50 values across multiple combinations highlight the high sensitivity of these antibodies for feline NT-proBNP detection.
C. Analytical performance of antibody pairs.
D. Specificity assessment across species. Direct ELISA analysis confirms strong binding to feline NT-proBNP while showing negligible or significantly reduced reactivity to canine and human NT-proBNP, demonstrating high assay specificity.
E. Stability testing under different storage conditions. Antibodies maintain consistent EC50 values after two months at 37 °C (lyophilized or liquid) and −80 °C, confirming excellent stability for long-term storage and reliable performance under diverse conditions.
GeneMedi's anti-Feline NT-proBNP antibody pairs demonstrate outstanding clinical detection performance across diverse Fc platforms.
GeneMedi's NT-proBNP immunoassay antibody pairs demonstrate outstanding performance in clinical sample detection, effectively differentiating between healthy and HCM feline plasma with high sensitivity and robust signal output.
The pairs exhibit excellent affinity and specificity across multiple configurations, including both human Fc-based and mouse Fc-tagged versions, consistently showing strong dose-response relationships and clear discrimination between sample types. This versatility and reliability make them ideal for cardiovascular disease diagnostic assays, particularly in veterinary and translational research settings.
Fig 2. GeneMedi's anti-Feline NT-proBNP antibody pairs demonstrate outstanding clinical detection performance across diverse Fc platforms.
A. NT-proBNP Antibody Pairs with Human Fc Tags. Human Fc-based antibody pairs exhibit significantly elevated NT-proBNP detection levels in HCM cat plasma versus healthy controls, with a strong dose-response relationship and high signal intensity confirming excellent affinity and specificity.
B. NT-proBNP Antibody Pairs with Mouse Fc Tags. Mouse Fc-tagged pairs (e.g., Coating Ab: Ab01 mFc; Detection Ab: Ab02/06 mFc) similarly distinguish healthy from HCM feline samples, showing high signal in diseased cohorts and demonstrating consistent versatility and robustness across Fc platforms.
What is NT-proBNP?
NT-proBNP (N-terminal pro-B-type natriuretic peptide) is an inactive cleavage fragment derived from proBNP, which is released from cardiomyocytes in response to myocardial stretch, wall stress, or volume overload. Unlike BNP, which is biologically active, NT-proBNP is more stable in circulation, making it suitable for diagnostic testing.
NT-proBNP in Cats and Dogs: Cardiac Physiology and Pathology
Studies on NT-proBNP have delineated species-specific patterns of release in response to myocardial stress in dogs and cats, providing a scientific basis for its clinical utility in diagnosing common feline and canine cardiomyopathies.
In physiology: At baseline, NT-proBNP is secreted at low concentrations, reflecting normal myocardial function. In pathology: In dogs and cats with cardiac disease, myocardial stretch and increased intracardiac pressure significantly elevate NT-proBNP levels.
Figure 1. Stages of Feline Cardiomyopathy
Species-specific considerations:
· In cats, hypertrophic cardiomyopathy (HCM) is the most common cardiac disease, often subclinical, and NT-proBNP can reflect early myocardial stress before clinical signs appear.
· In dogs, dilated cardiomyopathy (DCM), myxomatous mitral valve disease (MMVD)/degenerative mitral valve disease (DMVD), and heartworm disease cause progressive elevation of NT-proBNP.
Diagnostic Role of NT-proBNP in Cats and Dogs and its Relationship to Echocardiography
| Species | Reference Range (pmol/L) | Interpretation |
|---|---|---|
| Cats | ≤49 | Cardiomyopathy or congestive heart failure (CHF) is unlikely at this time. |
| 50-150 | Congestive heart failure ranks low on the differential for the current clinical signs. The presence of moderate or severe heart disease is also considered unlikely. | |
| ＞150 | The clinical assessment suggests that the signs are likely secondary to cardiac disease and congestive heart failure. Pursuing additional diagnostics is essential, specifically an echocardiogram to confirm the presence and type of cardiac disease. | |
| Dogs | ＜900 | In cases of low clinical suspicion, cardiac disease is considered unlikely. |
| 900-1800 | In the presence of signs highly suggestive of cardiac disease, further diagnostic workup (e.g., echocardiogram) is recommended. | |
| ＞1800 | High Probability of Cardiac Disease: Clinical signs are most consistent with underlying cardiac pathology. |
Note:
The interpretation of biomarker cut-off values is not absolute and should be approached cautiously because of significant overlap between disease states. These results only become meaningful when correlated with the complete clinical context, including the physical exam, history, and other diagnostic findings.
Complement to echocardiography:
· Echocardiography remains the gold standard for structural and functional cardiac diagnosis.
· NT-proBNP provides a non-invasive, rapid, and quantitative biochemical marker that can identify patients requiring further imaging.
· Combining NT-proBNP with echocardiography improves diagnostic accuracy, especially in borderline or early cases.
Clinical application of NT-proBNP:
a. Monitoring progression and prognosis in chronic cardiac disease.
b. Supporting differential diagnosis between respiratory and cardiac causes of dyspnea.
c. Providing guidance for treatment decisions and follow-up in both cats and dogs.
Disclaimer:
Disclaimer: The content of this article is for informational use only and is not a substitute for professional veterinary advice, diagnosis, or treatment. The needs of every pet are unique. For an accurate diagnosis and treatment plan tailored to your individual pet, please consult a licensed veterinarian.
Product list of GeneMedi's NT-proBNP products
| Catalog No. | Products Name | Detected Species | Disease/Condition | Products Type | Products Information |
| GMP-FEL-NT-proBNP-Ag | Feline NT-proBNP (N-terminal prohormone of brain natriuretic peptide) antigen | Cat/Feline | Heart failure, cardiac disease | peptide-(naked/BSA/OVA) | Details |
| GMP-FEL-NT-proBNP-Ab | Anti-Feline NT-proBNP (N-terminal prohormone of brain natriuretic peptide) antibody | Cat/Feline | Heart failure, cardiac disease | antibody(Fc/mFc) | Details |
| GMP-CAN-NT-proBNP-Ag | Canine NT-proBNP (N-terminal prohormone of brain natriuretic peptide) antigen | Dog/Canine | Heart failure, cardiac disease | peptide-(naked/BSA/OVA) | Details |
| GMP-CAN-NT-proBNP-Ab | Anti-Canine NT-proBNP (N-terminal prohormone of brain natriuretic peptide) antibody | Dog/Canine | Heart failure, cardiac disease | antibody(Fc/mFc) | Details |
| GMP-BOV-NT-proBNP-Ag | Bovine NT-proBNP (N-terminal prohormone of brain natriuretic peptide) antigen | Bovines/Cattle | Cardiac disease | peptide-(naked/BSA/OVA) | Details |
| GMP-BOV-NT-proBNP-Ab | Anti-Bovine NT-proBNP (N-terminal prohormone of brain natriuretic peptide) antibody | Bovines/Cattle | Cardiac disease | antibody(Fc/mFc) | Details |
*Note: 1. The bioactivity of the antigen, as demonstrated through its binding capabilities and role as an immunogen in sandwich ELISA, lateral-flow tests, and other immunoassays, serves as a control material in disease-related assessments. 2. The paired antibody demonstrates bioactivity by binding to its recombinant antigen, validated in ELISA as both a capture and detection antibody for disease testing.
